A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

H. Josh Jang, Galen Hostetter, Alexander W. Macfarlane, Zachary Madaj, Eric A. Ross, Toshinori Hinoue, Justin R. Kulchycki, Ryan S. Burgos, Mahvish Tafseer, R. Katherine Alpaugh, Candice L. Schwebel, Rutika Kokate, Daniel M. Geynisman, Matthew R. Zibelman, Pooja Ghatalia, Peter W. Nichols, Woonbok Chung, Jozef Madzo, Noah M. Hahn, David I. QuinnJean Pierre J. Issa, Michael J. Topper, Stephen B. Baylin, Hui Shen, Kerry S. Campbell, Peter A. Jones, Elizabeth R. Plimack

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology

Keyphrases